Literature DB >> 10962468

Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses?

R Flamholz1, H R Jeon, J M Baron, B W Baron.   

Abstract

Solvent/detergent treated plasma (S/DP) has reduced protein S activity (about 0.5 units/mL) as compared with fresh frozen plasma (FFP). When used as replacement fluid for repetitive therapeutic plasma exchange (PEX), e.g., in patients with thrombotic thrombocytopenic purpura (TTP), S/DP could lead to lowered protein S levels and, possibly, risk of hypercoagulable complications. We describe three patients with TTP who had low functional protein S (FPS) levels during PEX for TTP. Each developed one or more deep vein thromboses (DVTs) while receiving 100% S/DP or 50% S/DP and 50% cryosupernatant plasma (CSP) as replacement fluid. FPS levels rose when 100% CSP was substituted for S/DP. Our observations suggest that use of S/DP alone or in 50% combination with CSP as replacement fluid in PEX for TTP may lead to difficulty in maintaining safe FPS levels. Determination of risk of resulting clinically significant thrombotic events requires further study. Copyright 2000 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10962468     DOI: 10.1002/1098-1101(2000)15:3<169::aid-jca2>3.0.co;2-r

Source DB:  PubMed          Journal:  J Clin Apher        ISSN: 0733-2459            Impact factor:   2.821


  8 in total

Review 1.  Proceedings of a Consensus Conference: pathogen inactivation-making decisions about new technologies.

Authors:  Kathryn E Webert; Christine M Cserti; Judy Hannon; Yulia Lin; Katerina Pavenski; Jacob M Pendergrast; Morris A Blajchman
Journal:  Transfus Med Rev       Date:  2008-01

Review 2.  Recommendations for the transfusion of plasma and platelets.

Authors:  Giancarlo Liumbruno; Francesco Bennardello; Angela Lattanzio; Pierluigi Piccoli; Gina Rossetti
Journal:  Blood Transfus       Date:  2009-04       Impact factor: 3.443

3.  Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma.

Authors:  Giancarlo Maria Liumbruno; Maria Laura Sodini; Giuliano Grazzini
Journal:  Blood Transfus       Date:  2008-01       Impact factor: 3.443

Review 4.  Health Technology Assessment of pathogen reduction technologies applied to plasma for clinical use.

Authors:  Americo Cicchetti; Alexandra Berrino; Marina Casini; Paola Codella; Giuseppina Facco; Alessandra Fiore; Giuseppe Marano; Marco Marchetti; Emanuela Midolo; Roberta Minacori; Pietro Refolo; Federica Romano; Matteo Ruggeri; Dario Sacchini; Antonio G Spagnolo; Irene Urbina; Stefania Vaglio; Giuliano Grazzini; Giancarlo M Liumbruno
Journal:  Blood Transfus       Date:  2016-07       Impact factor: 3.443

5.  Macrovascular thrombosis in critically ill patients with thrombotic micro-angiopathies.

Authors:  Laurent Camous; Agnès Veyradier; Michael Darmon; Lionel Galicier; Eric Mariotte; Emmanuel Canet; Nathalie Parquet; Élie Azoulay
Journal:  Intern Emerg Med       Date:  2012-10-07       Impact factor: 3.397

6.  Pharmacologic reversal of warfarin-associated coagulopathy in geriatric patients with hip fractures: a retrospective study of thromboembolic events, postoperative complications, and time to surgery.

Authors:  Mark A Vitale; Corinne Vanbeek; John H Spivack; Bin Cheng; Jeffrey A Geller
Journal:  Geriatr Orthop Surg Rehabil       Date:  2011-07

Review 7.  Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data.

Authors:  José Luis Arroyo; Eva Martínez; Cristina Amunárriz; Carmen Muñoz; Iñigo Romón; Ignacio Álvarez; José María García
Journal:  Transfus Apher Sci       Date:  2020-04-12       Impact factor: 1.764

8.  Solvent/detergent plasma: pharmaceutical characteristics and clinical experience.

Authors:  Giancarlo Maria Liumbruno; Massimo Franchini
Journal:  J Thromb Thrombolysis       Date:  2015-01       Impact factor: 2.300

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.